Skip to main content
Top
Published in: Trials 1/2011

Open Access 01-12-2011 | Methodology

Sample size requirements for separating out the effects of combination treatments: Randomised controlled trials of combination therapy vs. standard treatment compared to factorial designs for patients with tuberculous meningitis

Authors: Marcel Wolbers, Dorothee Heemskerk, Tran Thi Hong Chau, Nguyen Thi Bich Yen, Maxine Caws, Jeremy Farrar, Jeremy Day

Published in: Trials | Issue 1/2011

Login to get access

Abstract

Background

In certain diseases clinical experts may judge that the intervention with the best prospects is the addition of two treatments to the standard of care. This can either be tested with a simple randomized trial of combination versus standard treatment or with a 2 × 2 factorial design.

Methods

We compared the two approaches using the design of a new trial in tuberculous meningitis as an example. In that trial the combination of 2 drugs added to standard treatment is assumed to reduce the hazard of death by 30% and the sample size of the combination trial to achieve 80% power is 750 patients. We calculated the power of corresponding factorial designs with one- to sixteen-fold the sample size of the combination trial depending on the contribution of each individual drug to the combination treatment effect and the strength of an interaction between the two.

Results

In the absence of an interaction, an eight-fold increase in sample size for the factorial design as compared to the combination trial is required to get 80% power to jointly detect effects of both drugs if the contribution of the less potent treatment to the total effect is at least 35%. An eight-fold sample size increase also provides a power of 76% to detect a qualitative interaction at the one-sided 10% significance level if the individual effects of both drugs are equal. Factorial designs with a lower sample size have a high chance to be underpowered, to show significance of only one drug even if both are equally effective, and to miss important interactions.

Conclusions

Pragmatic combination trials of multiple interventions versus standard therapy are valuable in diseases with a limited patient pool if all interventions test the same treatment concept, it is considered likely that either both or none of the individual interventions are effective, and only moderate drug interactions are suspected. An adequately powered 2 × 2 factorial design to detect effects of individual drugs would require at least 8-fold the sample size of the combination trial.

Trial registration

Current Controlled Trials ISRCTN61649292
Appendix
Available only for authorised users
Literature
1.
go back to reference Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, Nguyen QH, Nguyen TT, Nguyen NH, Nguyen TN, Nguyen NL, Nguyen HD, Vu NT, Cao HH, Tran TH, Pham PM, Nguyen TD, Stepniewska K, White NJ, Tran TH, Farrar JJ: Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004, 351: 1741-1751. 10.1056/NEJMoa040573.CrossRefPubMed Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, Nguyen QH, Nguyen TT, Nguyen NH, Nguyen TN, Nguyen NL, Nguyen HD, Vu NT, Cao HH, Tran TH, Pham PM, Nguyen TD, Stepniewska K, White NJ, Tran TH, Farrar JJ: Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004, 351: 1741-1751. 10.1056/NEJMoa040573.CrossRefPubMed
2.
go back to reference Heemskerk D, Day J, Caws M, Tran TH, Tran THC, Nguyen HD, Nguyen TBY, Nguyen DB, Pouplin T, Wolbers M, Farrar JJ: Intensified treatment with high dose Rifampicin and Levofloxacin compared to standard treatment for adult patients with Tuberculous Meningitis (TBM-IT): protocol for a randomized controlled trial. Trials. 2011, 12: 25-10.1186/1745-6215-12-25.CrossRefPubMedPubMedCentral Heemskerk D, Day J, Caws M, Tran TH, Tran THC, Nguyen HD, Nguyen TBY, Nguyen DB, Pouplin T, Wolbers M, Farrar JJ: Intensified treatment with high dose Rifampicin and Levofloxacin compared to standard treatment for adult patients with Tuberculous Meningitis (TBM-IT): protocol for a randomized controlled trial. Trials. 2011, 12: 25-10.1186/1745-6215-12-25.CrossRefPubMedPubMedCentral
3.
go back to reference Piantadosi S: Clinical Trials: A Methodologic Perspective. 2005, Wiley-Interscience, SecondCrossRef Piantadosi S: Clinical Trials: A Methodologic Perspective. 2005, Wiley-Interscience, SecondCrossRef
4.
go back to reference Brittain E, Wittes J: Factorial designs in clinical trials: the effects of non-compliance and subadditivity. Stat Med. 1989, 8: 161-171. 10.1002/sim.4780080204.CrossRefPubMed Brittain E, Wittes J: Factorial designs in clinical trials: the effects of non-compliance and subadditivity. Stat Med. 1989, 8: 161-171. 10.1002/sim.4780080204.CrossRefPubMed
5.
go back to reference Green S, Liu PY, O'Sullivan J: Factorial design considerations. J Clin Oncol. 2002, 20: 3424-3430. 10.1200/JCO.2002.03.003.CrossRefPubMed Green S, Liu PY, O'Sullivan J: Factorial design considerations. J Clin Oncol. 2002, 20: 3424-3430. 10.1200/JCO.2002.03.003.CrossRefPubMed
6.
go back to reference Simon R, Freedman LS: Bayesian design and analysis of two × two factorial clinical trials. Biometrics. 1997, 53: 456-464. 10.2307/2533949.CrossRefPubMed Simon R, Freedman LS: Bayesian design and analysis of two × two factorial clinical trials. Biometrics. 1997, 53: 456-464. 10.2307/2533949.CrossRefPubMed
7.
go back to reference Collett D: Modeling Survival Data in Medical Research. 2003, Chapman & Hall/CRC, Second Collett D: Modeling Survival Data in Medical Research. 2003, Chapman & Hall/CRC, Second
9.
go back to reference Chakraborty B, Collins LM, Strecher VJ, Murphy SA: Developing multicomponent interventions using fractional factorial designs. Stat Med. 2009, 28: 2687-2708. 10.1002/sim.3643.CrossRefPubMedPubMedCentral Chakraborty B, Collins LM, Strecher VJ, Murphy SA: Developing multicomponent interventions using fractional factorial designs. Stat Med. 2009, 28: 2687-2708. 10.1002/sim.3643.CrossRefPubMedPubMedCentral
10.
go back to reference Misra UK, Kalita J, Nair PP: Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial. J Neurol Sci. 293: 12-17. 10.1016/j.jns.2010.03.025. Misra UK, Kalita J, Nair PP: Role of aspirin in tuberculous meningitis: a randomized open label placebo controlled trial. J Neurol Sci. 293: 12-17. 10.1016/j.jns.2010.03.025.
11.
go back to reference Bretz F, Koenig F, Brannath W, Glimm E, Posch M: Adaptive designs for confirmatory clinical trials. Stat Med. 2009, 28: 1181-1217. 10.1002/sim.3538.CrossRefPubMed Bretz F, Koenig F, Brannath W, Glimm E, Posch M: Adaptive designs for confirmatory clinical trials. Stat Med. 2009, 28: 1181-1217. 10.1002/sim.3538.CrossRefPubMed
Metadata
Title
Sample size requirements for separating out the effects of combination treatments: Randomised controlled trials of combination therapy vs. standard treatment compared to factorial designs for patients with tuberculous meningitis
Authors
Marcel Wolbers
Dorothee Heemskerk
Tran Thi Hong Chau
Nguyen Thi Bich Yen
Maxine Caws
Jeremy Farrar
Jeremy Day
Publication date
01-12-2011
Publisher
BioMed Central
Published in
Trials / Issue 1/2011
Electronic ISSN: 1745-6215
DOI
https://doi.org/10.1186/1745-6215-12-26

Other articles of this Issue 1/2011

Trials 1/2011 Go to the issue